$ATAI
ATAI Life Sciences NV Stock $atai

$atai Overview Financials Valuation SEC Filings Company Website

2022 Q3 Form 10-Q Financial Statement

#000095017022017253 Filed on August 15, 2022

Income Statement

Concept	2022 Q3	2022 Q2	2021 Q4
Revenue	$24.00K	$170.0K	$230.0K
YoY Change	-90.98%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$19.42M	$17.22M	$25.88M
YoY Change	-4.17%	-53.87%	-64.05%
% of Gross Profit
Research & Development	$19.03M	$17.95M	$12.98M
YoY Change	42.39%	12.0%	287.52%
% of Gross Profit
Depreciation & Amortization	$36.00K	$19.00K	$29.00K
YoY Change	-614.29%	-24.0%	107.14%
% of Gross Profit
Operating Expenses	$38.45M	$35.53M	$38.86M
YoY Change	14.33%	-42.06%	-48.42%
Operating Profit	-$38.42M	-$35.36M
YoY Change	15.17%	-42.34%
Interest Expense	$4.615M	$4.999M	-$3.656M
YoY Change	-27.89%	-193.88%	-1067.2%
% of Operating Profit
Other Income/Expense, Net	$5.289M	$4.551M	$252.0K
YoY Change	-23.2%	-176.08%	-106.5%
Pretax Income	-$33.13M	-$30.81M	-$48.58M
YoY Change	25.16%	-54.23%	-46.76%
Income Tax	$135.0K	$51.00K	-$4.421M
% Of Pretax Income
Net Earnings	-$33.89M	-$36.62M	-$88.88M
YoY Change	8.76%	-24.44%	2.64%
Net Earnings / Revenue	-141195.83%	-21540.0%	-38642.17%
Basic Earnings Per Share	-$0.22	-$0.24
Diluted Earnings Per Share	-$0.22	-$0.24	-$592.3K
COMMON SHARES
Basic Shares Outstanding	161.8M	154.0M	160.3M
Diluted Shares Outstanding	156.6M	154.0M

Balance Sheet

Concept	2022 Q3	2022 Q2	2021 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$304.1M	$312.5M	$362.3M
YoY Change	-29.34%	-31.11%
Cash & Equivalents	$142.5M	$84.10M	$362.3M
Short-Term Investments	$161.5M	$228.4M
Other Short-Term Assets	$1.367M	$1.322M	$756.0K
YoY Change	196.53%	-49.54%	36.46%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$317.5M	$323.6M	$375.1M
YoY Change	-28.15%	-29.28%	276.79%
LONG-TERM ASSETS
Property, Plant & Equipment	$728.0K	$303.0K	$149.0K
YoY Change	427.54%	-8.46%	109.86%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$0.00	$1.162M	$16.13M
YoY Change	-100.0%	-97.28%
Other Assets	$8.738M	$7.590M	$7.341M
YoY Change	592.39%	1001.6%	2065.49%
Total Long-Term Assets	$25.12M	$25.33M	$39.08M
YoY Change	-40.56%	-47.64%	225.7%
TOTAL ASSETS
Total Short-Term Assets	$317.5M	$323.6M	$375.1M
Total Long-Term Assets	$25.12M	$25.33M	$39.08M
Total Assets	$342.6M	$348.9M	$414.2M
YoY Change	-29.23%	-31.04%	271.29%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.511M	$2.738M	$6.004M
YoY Change	77.86%	-55.85%	94.75%
Accrued Expenses	$22.14M	$18.91M	$14.83M
YoY Change	69.35%	190.92%	60.92%
Deferred Revenue
YoY Change
Short-Term Debt	$161.5M	$228.4M	$0.00
YoY Change	424900.0%
Long-Term Debt Due	$0.00
YoY Change	-100.0%
Total Short-Term Liabilities	$25.91M	$21.96M	$20.94M
YoY Change	69.18%	54.79%	70.23%
LONG-TERM LIABILITIES
Long-Term Debt	$15.00M	$619.0K	$743.0K
YoY Change	1775.13%	-47.36%
Other Long-Term Liabilities	$3.695M	$3.900M	$4.097M
YoY Change	12.48%	-31.64%
Total Long-Term Liabilities	$3.695M	$3.900M	$4.097M
YoY Change	12.48%	-43.32%
TOTAL LIABILITIES
Total Short-Term Liabilities	$25.91M	$21.96M	$20.94M
Total Long-Term Liabilities	$3.695M	$3.900M	$4.097M
Total Liabilities	$46.52M	$28.81M	$28.21M
YoY Change	117.89%	-7.38%	74.33%
SHAREHOLDERS EQUITY
Retained Earnings	-$465.2M	-$431.3M	-$357.8M
YoY Change	72.99%		88.32%
Common Stock	$18.55M	$18.11M	$18.00M
YoY Change	3.83%		34.62%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$289.4M	$311.7M	$376.9M
YoY Change
Total Liabilities & Shareholders Equity	$342.6M	$348.9M	$414.2M
YoY Change	-29.23%	-31.04%	271.29%

Cashflow Statement

Concept	2022 Q3	2022 Q2	2021 Q4
OPERATING ACTIVITIES
Net Income	-$33.89M	-$36.62M	-$88.88M
YoY Change	8.76%	-24.44%	2.64%
Depreciation, Depletion And Amortization	$36.00K	$19.00K	$29.00K
YoY Change	-614.29%	-24.0%	107.14%
Cash From Operating Activities	-$28.05M	-$21.93M	-$20.51M
YoY Change	-0.23%	49.94%	230.05%
INVESTING ACTIVITIES
Capital Expenditures	-$529.0K	-$216.0K	-$357.0K
YoY Change	66.35%	-52.32%	614.0%
Acquisitions
YoY Change
Other Investing Activities	$66.58M	-$18.00M	-$48.28M
YoY Change	-22592.91%	-43.0%	1165.09%
Cash From Investing Activities	$66.05M	-$18.21M	-$48.63M
YoY Change	-10857.33%	-43.13%	1157.97%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	19.78M	1.794M	1.723M
YoY Change	410.21%	-99.56%	-97.9%
NET CHANGE
Cash From Operating Activities	-28.05M	-21.93M	-20.51M
Cash From Investing Activities	66.05M	-18.21M	-48.63M
Cash From Financing Activities	19.78M	1.794M	1.723M
Net Change In Cash	57.79M	-38.35M	-67.42M
YoY Change	-332.57%	-110.72%	-193.77%
FREE CASH FLOW
Cash From Operating Activities	-$28.05M	-$21.93M	-$20.51M
Capital Expenditures	-$529.0K	-$216.0K	-$357.0K
Free Cash Flow	-$27.52M	-$21.72M	-$20.15M
YoY Change	-0.99%	53.2%	226.93%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Amendment Flag AmendmentFlag	false
	dei	Amendment Flag AmendmentFlag	false
CY2022Q2	us-gaap	Assets Current AssetsCurrent	323608000
CY2021Q4	us-gaap	Assets Current AssetsCurrent	375082000
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	303000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	149000
CY2022Q2	us-gaap	Equity Method Investments EquityMethodInvestments	1162000
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Entity Central Index Key EntityCentralIndexKey	0001840904
CY2021Q2	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	1654
CY2021Q2	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	1350
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	00000
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	00-0000000
CY2022Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-06-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-40493
	dei	Entity Registrant Name EntityRegistrantName	ATAI Life Sciences N.V.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	P7
	dei	Entity Address Address Line1 EntityAddressAddressLine1	ATAI Life Sciences N.V. c/o Mindspace
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Krausenstraße 9-10
	dei	Entity Address City Or Town EntityAddressCityOrTown	Berlin
	dei	Entity Address Country EntityAddressCountry	DE
	dei	City Area Code CityAreaCode	49 89
	dei	Local Phone Number LocalPhoneNumber	2153 9035
	dei	Security12b Title Security12bTitle	Common shares, par value €0.10 per share
	dei	Trading Symbol TradingSymbol	ATAI
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	false
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	161819984
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	84132000
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	362266000
CY2022Q2	atai	Debt Securities Carried At Fair Value DebtSecuritiesCarriedAtFairValue	228354000
CY2021Q4	atai	Debt Securities Carried At Fair Value DebtSecuritiesCarriedAtFairValue	0
CY2022Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	11122000
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	11903000
CY2022Q2	us-gaap	Notes And Loans Receivable Net Current NotesAndLoansReceivableNetCurrent	0
CY2021Q4	us-gaap	Notes And Loans Receivable Net Current NotesAndLoansReceivableNetCurrent	913000
CY2021Q4	us-gaap	Equity Method Investments EquityMethodInvestments	16131000
CY2022Q2	us-gaap	Other Long Term Investments OtherLongTermInvestments	9233000
	dei	Entity Central Index Key EntityCentralIndexKey	0001840904
CY2021Q2	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	1654
CY2021Q2	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	1350
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	00000
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	00-0000000
CY2022Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-40493
	dei	Entity Registrant Name EntityRegistrantName	ATAI Life Sciences N.V.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	P7
	dei	Entity Address Address Line1 EntityAddressAddressLine1	ATAI Life Sciences N.V. c/o Mindspace
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Krausenstraße 9-10
	dei	Entity Address City Or Town EntityAddressCityOrTown	Berlin
	dei	Entity Address Country EntityAddressCountry	DE
	dei	City Area Code CityAreaCode	49 89
	dei	Local Phone Number LocalPhoneNumber	2153 9035
	dei	Security12b Title Security12bTitle	Common shares, par value €0.10 per share
	dei	Trading Symbol TradingSymbol	ATAI
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	false
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	161819984
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	84132000
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	362266000
CY2022Q2	atai	Debt Securities Carried At Fair Value DebtSecuritiesCarriedAtFairValue	228354000
CY2021Q4	atai	Debt Securities Carried At Fair Value DebtSecuritiesCarriedAtFairValue	0
CY2022Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	11122000
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	11903000
CY2022Q2	us-gaap	Notes And Loans Receivable Net Current NotesAndLoansReceivableNetCurrent	0
CY2021Q4	us-gaap	Notes And Loans Receivable Net Current NotesAndLoansReceivableNetCurrent	913000
CY2022Q2	us-gaap	Assets Current AssetsCurrent	323608000
CY2021Q4	us-gaap	Assets Current AssetsCurrent	375082000
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	303000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	149000
CY2022Q2	us-gaap	Equity Method Investments EquityMethodInvestments	1162000
CY2021Q4	us-gaap	Equity Method Investments EquityMethodInvestments	16131000
CY2022Q2	us-gaap	Other Long Term Investments OtherLongTermInvestments	9233000
CY2021Q4	us-gaap	Other Long Term Investments OtherLongTermInvestments	11628000
CY2022Q2	us-gaap	Notes Receivable Related Parties Noncurrent NotesReceivableRelatedPartiesNoncurrent	7040000
CY2021Q4	us-gaap	Notes Receivable Related Parties Noncurrent NotesReceivableRelatedPartiesNoncurrent	3835000
CY2021Q4	us-gaap	Other Long Term Investments OtherLongTermInvestments	11628000
CY2022Q2	us-gaap	Notes Receivable Related Parties Noncurrent NotesReceivableRelatedPartiesNoncurrent	7040000
CY2021Q4	us-gaap	Notes Receivable Related Parties Noncurrent NotesReceivableRelatedPartiesNoncurrent	3835000
CY2022Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	7590000
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	7341000
CY2022Q2	us-gaap	Assets Assets	348936000
CY2021Q4	us-gaap	Assets Assets	414166000
CY2022Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	2738000
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	6004000
CY2022Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	18913000
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	14829000
CY2022Q2	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	0
CY2021Q4	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	51000
CY2022Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	306000
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	51000
CY2022Q2	us-gaap	Liabilities Current LiabilitiesCurrent	21957000
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	20935000
CY2022Q2	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	2338000
CY2021Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	2432000
CY2022Q2	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	619000
CY2021Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	743000
CY2022Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	3900000
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	4097000
CY2022Q2	us-gaap	Liabilities Liabilities	28814000
CY2021Q4	us-gaap	Liabilities Liabilities	28207000
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.10
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.10
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.12
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.12
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	750000000
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	750000000
CY2022Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	161727785
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	161727785
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	160677001
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	160677001
CY2022Q2	us-gaap	Common Stock Value CommonStockValue	18114000
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	18002000
CY2022Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	746042000
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	725045000
CY2022Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-21191000
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-8336000
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-431290000
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-357803000
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	311675000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	376908000
CY2022Q2	us-gaap	Minority Interest MinorityInterest	8447000
CY2022Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	7590000
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	7341000
CY2022Q2	us-gaap	Assets Assets	348936000
CY2021Q4	us-gaap	Assets Assets	414166000
CY2022Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	2738000
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	6004000
CY2022Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	18913000
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	14829000
CY2022Q2	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	0
CY2021Q4	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	51000
CY2022Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	306000
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	51000
CY2022Q2	us-gaap	Liabilities Current LiabilitiesCurrent	21957000
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	20935000
CY2022Q2	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	2338000
CY2021Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	2432000
CY2022Q2	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	619000
CY2021Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	743000
CY2022Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	3900000
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	4097000
CY2022Q2	us-gaap	Liabilities Liabilities	28814000
CY2021Q4	us-gaap	Liabilities Liabilities	28207000
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.10
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.10
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.12
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.12
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	750000000
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	750000000
CY2022Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	161727785
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	161727785
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	160677001
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	160677001
CY2022Q2	us-gaap	Common Stock Value CommonStockValue	18114000
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	18002000
CY2022Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	746042000
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	725045000
CY2022Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-21191000
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-8336000
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-431290000
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-357803000
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	311675000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	376908000
CY2022Q2	us-gaap	Minority Interest MinorityInterest	8447000
CY2021Q4	us-gaap	Minority Interest MinorityInterest	9051000
CY2022Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	320122000
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	385959000
CY2021Q4	us-gaap	Minority Interest MinorityInterest	9051000
CY2022Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	320122000
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	385959000
CY2022Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	348936000
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	414166000
CY2022Q2	us-gaap	Revenues Revenues	170000
CY2021Q2	us-gaap	Revenues Revenues	0
	us-gaap	Revenues Revenues	170000
	us-gaap	Revenues Revenues	19880000
CY2022Q2	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	17949000
CY2021Q2	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	16026000
	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	33409000
	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	21611000
	atai	Acquisition Of In Process Research And Development AcquisitionOfInProcessResearchAndDevelopment	357000
	atai	Acquisition Of In Process Research And Development AcquisitionOfInProcessResearchAndDevelopment	8934000
CY2022Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	17221000
CY2021Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	37331000
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	35203000
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	46604000
CY2022Q2	us-gaap	Operating Expenses OperatingExpenses	35527000
CY2021Q2	us-gaap	Operating Expenses OperatingExpenses	61319000
	us-gaap	Operating Expenses OperatingExpenses	68969000
	us-gaap	Operating Expenses OperatingExpenses	77149000
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-35357000
CY2021Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-61319000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-68799000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-57269000
CY2022Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	117000
CY2021Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	35000
	us-gaap	Investment Income Interest InvestmentIncomeInterest	215000
	us-gaap	Investment Income Interest InvestmentIncomeInterest	72000
CY2022Q2	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-95000
CY2021Q2	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	911000
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-95000
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	660000
CY2022Q2	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	0
CY2021Q2	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	0
	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	0
	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	-41000
CY2022Q2	atai	Change In Fair Value Of Warrant Liability ChangeInFairValueOfWarrantLiability	-53000
CY2021Q2	atai	Change In Fair Value Of Warrant Liability ChangeInFairValueOfWarrantLiability	0
	atai	Change In Fair Value Of Warrant Liability ChangeInFairValueOfWarrantLiability	-53000
	atai	Change In Fair Value Of Warrant Liability ChangeInFairValueOfWarrantLiability	0
CY2022Q2	us-gaap	Increase Decrease In Debt Securities Trading IncreaseDecreaseInDebtSecuritiesTrading	-584000
CY2021Q2	us-gaap	Increase Decrease In Debt Securities Trading IncreaseDecreaseInDebtSecuritiesTrading	0
	us-gaap	Increase Decrease In Debt Securities Trading IncreaseDecreaseInDebtSecuritiesTrading	-1324000
	us-gaap	Increase Decrease In Debt Securities Trading IncreaseDecreaseInDebtSecuritiesTrading	0
CY2022Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	348936000
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	414166000
CY2022Q2	us-gaap	Revenues Revenues	170000
CY2021Q2	us-gaap	Revenues Revenues	0
	us-gaap	Revenues Revenues	170000
	us-gaap	Revenues Revenues	19880000
CY2022Q2	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	17949000
CY2021Q2	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	16026000
	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	33409000
	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	21611000
CY2022Q2	atai	Acquisition Of In Process Research And Development AcquisitionOfInProcessResearchAndDevelopment	357000
CY2021Q2	atai	Acquisition Of In Process Research And Development AcquisitionOfInProcessResearchAndDevelopment	7962000
	atai	Acquisition Of In Process Research And Development AcquisitionOfInProcessResearchAndDevelopment	357000
	atai	Acquisition Of In Process Research And Development AcquisitionOfInProcessResearchAndDevelopment	8934000
CY2022Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	17221000
CY2021Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	37331000
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	35203000
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	46604000
CY2022Q2	us-gaap	Operating Expenses OperatingExpenses	35527000
CY2021Q2	us-gaap	Operating Expenses OperatingExpenses	61319000
	us-gaap	Operating Expenses OperatingExpenses	68969000
	us-gaap	Operating Expenses OperatingExpenses	77149000
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-35357000
CY2021Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-61319000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-68799000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-57269000
CY2022Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	117000
CY2021Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	35000
	us-gaap	Investment Income Interest InvestmentIncomeInterest	215000
	us-gaap	Investment Income Interest InvestmentIncomeInterest	72000
CY2022Q2	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-95000
CY2021Q2	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	911000
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-95000
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	660000
CY2022Q2	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	0
CY2021Q2	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	0
	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	0
	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	-41000
CY2022Q2	atai	Change In Fair Value Of Warrant Liability ChangeInFairValueOfWarrantLiability	-53000
CY2021Q2	atai	Change In Fair Value Of Warrant Liability ChangeInFairValueOfWarrantLiability	0
	atai	Change In Fair Value Of Warrant Liability ChangeInFairValueOfWarrantLiability	-53000
	atai	Change In Fair Value Of Warrant Liability ChangeInFairValueOfWarrantLiability	0
CY2022Q2	us-gaap	Increase Decrease In Debt Securities Trading IncreaseDecreaseInDebtSecuritiesTrading	-584000
CY2021Q2	us-gaap	Increase Decrease In Debt Securities Trading IncreaseDecreaseInDebtSecuritiesTrading	0
	us-gaap	Increase Decrease In Debt Securities Trading IncreaseDecreaseInDebtSecuritiesTrading	-1324000
	us-gaap	Increase Decrease In Debt Securities Trading IncreaseDecreaseInDebtSecuritiesTrading	0
CY2022Q2	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	0
CY2022Q2	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	0
CY2021Q2	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	-5460000
	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	0
	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	-5460000
CY2022Q2	atai	Gain Loss On Conversion Of Notes Related Party GainLossOnConversionOfNotesRelatedParty	0
CY2021Q2	atai	Gain Loss On Conversion Of Notes Related Party GainLossOnConversionOfNotesRelatedParty	-513000
	atai	Gain Loss On Conversion Of Notes Related Party GainLossOnConversionOfNotesRelatedParty	0
	atai	Gain Loss On Conversion Of Notes Related Party GainLossOnConversionOfNotesRelatedParty	-513000
CY2022Q2	us-gaap	Variable Interest Entity Initial Consolidation Gain Or Loss VariableInterestEntityInitialConsolidationGainOrLoss	0
CY2021Q2	us-gaap	Variable Interest Entity Initial Consolidation Gain Or Loss VariableInterestEntityInitialConsolidationGainOrLoss	3543000
	us-gaap	Variable Interest Entity Initial Consolidation Gain Or Loss VariableInterestEntityInitialConsolidationGainOrLoss	0
	us-gaap	Variable Interest Entity Initial Consolidation Gain Or Loss VariableInterestEntityInitialConsolidationGainOrLoss	3543000
CY2022Q2	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	4882000
CY2021Q2	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-2558000
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	7045000
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-1068000
CY2022Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-12000
CY2021Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-118000
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-12000
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-234000
CY2022Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	4551000
CY2021Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-5982000
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	6072000
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-4279000
CY2022Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-30806000
CY2021Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-67301000
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-62727000
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-61548000
CY2022Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	51000
CY2021Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	58000
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	92000
CY2022Q2	us-gaap	Equity Method Investment Realized Gain Loss On Disposal EquityMethodInvestmentRealizedGainLossOnDisposal	-0
CY2021Q2	us-gaap	Equity Method Investment Realized Gain Loss On Disposal EquityMethodInvestmentRealizedGainLossOnDisposal	16923000
	us-gaap	Equity Method Investment Realized Gain Loss On Disposal EquityMethodInvestmentRealizedGainLossOnDisposal	-0
	us-gaap	Equity Method Investment Realized Gain Loss On Disposal EquityMethodInvestmentRealizedGainLossOnDisposal	16923000
CY2022Q2	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-6652000
CY2021Q2	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-2937000
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-12248000
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-4640000
CY2022Q2	us-gaap	Profit Loss ProfitLoss	-37509000
CY2021Q2	us-gaap	Profit Loss ProfitLoss	-53373000
	us-gaap	Profit Loss ProfitLoss	-75067000
	us-gaap	Profit Loss ProfitLoss	-49329000
CY2022Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-891000
CY2021Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-4912000
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-1580000
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-1556000
CY2021Q2	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	-5460000
	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	0
	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	-5460000
CY2022Q2	atai	Gain Loss On Conversion Of Notes Related Party GainLossOnConversionOfNotesRelatedParty	0
CY2021Q2	atai	Gain Loss On Conversion Of Notes Related Party GainLossOnConversionOfNotesRelatedParty	-513000
	atai	Gain Loss On Conversion Of Notes Related Party GainLossOnConversionOfNotesRelatedParty	0
	atai	Gain Loss On Conversion Of Notes Related Party GainLossOnConversionOfNotesRelatedParty	-513000
CY2022Q2	us-gaap	Variable Interest Entity Initial Consolidation Gain Or Loss VariableInterestEntityInitialConsolidationGainOrLoss	0
CY2021Q2	us-gaap	Variable Interest Entity Initial Consolidation Gain Or Loss VariableInterestEntityInitialConsolidationGainOrLoss	3543000
	us-gaap	Variable Interest Entity Initial Consolidation Gain Or Loss VariableInterestEntityInitialConsolidationGainOrLoss	0
	us-gaap	Variable Interest Entity Initial Consolidation Gain Or Loss VariableInterestEntityInitialConsolidationGainOrLoss	3543000
CY2022Q2	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	4882000
CY2021Q2	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-2558000
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	7045000
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-1068000
CY2022Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-12000
CY2021Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-118000
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-12000
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-234000
CY2022Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	4551000
CY2021Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-5982000
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	6072000
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-4279000
CY2022Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-30806000
CY2021Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-67301000
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-62727000
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-61548000
CY2022Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	51000
CY2021Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	58000
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	92000
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	64000
CY2022Q2	us-gaap	Equity Method Investment Realized Gain Loss On Disposal EquityMethodInvestmentRealizedGainLossOnDisposal	-0
CY2021Q2	us-gaap	Equity Method Investment Realized Gain Loss On Disposal EquityMethodInvestmentRealizedGainLossOnDisposal	16923000
	us-gaap	Equity Method Investment Realized Gain Loss On Disposal EquityMethodInvestmentRealizedGainLossOnDisposal	-0
	us-gaap	Equity Method Investment Realized Gain Loss On Disposal EquityMethodInvestmentRealizedGainLossOnDisposal	16923000
CY2022Q2	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-6652000
CY2021Q2	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-2937000
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-12248000
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-4640000
CY2022Q2	us-gaap	Profit Loss ProfitLoss	-37509000
CY2021Q2	us-gaap	Profit Loss ProfitLoss	-53373000
	us-gaap	Profit Loss ProfitLoss	-75067000
	us-gaap	Profit Loss ProfitLoss	-49329000
CY2022Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-891000
CY2021Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-4912000
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-1580000
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-1556000
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-36618000
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-48461000
	us-gaap	Net Income Loss NetIncomeLoss	-73487000
	us-gaap	Net Income Loss NetIncomeLoss	-47773000
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.24
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.24
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.37
CY2021Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.37
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.48
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.48
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.38
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.38
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	153971202
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	153971202
CY2021Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	132265075
CY2021Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	132265075
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	153751456
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	153751456
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	125797732
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	125797732
CY2022Q2	us-gaap	Profit Loss ProfitLoss	-37509000
CY2021Q2	us-gaap	Profit Loss ProfitLoss	-53373000
	us-gaap	Profit Loss ProfitLoss	-75067000
	us-gaap	Profit Loss ProfitLoss	-49329000
CY2022Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-8482000
CY2021Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	2110000
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-12855000
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-1916000
CY2022Q2	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-45991000
CY2021Q2	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-51263000
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-87922000
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-51245000
CY2022Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	891000
CY2021Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	4912000
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	1580000
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	1556000
CY2022Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest	30000
CY2021Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest	150000
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest	19000
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest	-34000
CY2022Q2	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-861000
CY2021Q2	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-4762000
	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-1561000
	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-1590000
CY2022Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-45130000
CY2021Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-46501000
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-86361000
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-36618000
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-48461000
	us-gaap	Net Income Loss NetIncomeLoss	-73487000
	us-gaap	Net Income Loss NetIncomeLoss	-47773000
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.24
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.24
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.37
CY2021Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.37
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.48
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.48
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.38
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.38
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	153971202
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	153971202
CY2021Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	132265075
CY2021Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	132265075
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	153751456
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	153751456
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	125797732
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	125797732
CY2022Q2	us-gaap	Profit Loss ProfitLoss	-37509000
	us-gaap	Profit Loss ProfitLoss	-75067000
	us-gaap	Profit Loss ProfitLoss	-49329000
CY2022Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-8482000
CY2021Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	2110000
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-12855000
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-1916000
CY2022Q2	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-45991000
CY2021Q2	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-51263000
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-87922000
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-51245000
CY2022Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	891000
CY2021Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	4912000
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	1580000
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	1556000
CY2022Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest	30000
CY2021Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest	150000
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest	19000
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest	-34000
CY2022Q2	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-861000
CY2021Q2	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-4762000
	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-1561000
	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-1590000
CY2022Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-45130000
CY2021Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-46501000
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-86361000
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-49655000
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-49655000
CY2021Q4	atai	Stockholder Equity Including Portion Attributable To Noncontrolling Interest StockholderEquityIncludingPortionAttributableToNoncontrollingInterest	385959000
CY2022Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	132000
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	10208000
CY2022Q1	atai	Foreign Currency Translation Adjustment Net Of Tax ForeignCurrencyTranslationAdjustmentNetOfTax	-4384000
CY2022Q1	us-gaap	Net Income Loss Including Portion Attributable To Nonredeemable Noncontrolling Interest NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest	-37558000
CY2022Q1	atai	Stockholder Equity Including Portion Attributable To Noncontrolling Interest StockholderEquityIncludingPortionAttributableToNoncontrollingInterest	354357000
CY2022Q2	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	1140000
CY2022Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	118000
CY2022Q2	atai	Issuance Of Subsidiary Preferred Shares IssuanceOfSubsidiaryPreferredShares	600000
CY2022Q2	atai	Issuance Of Subsidiary Common Shares IssuanceOfSubsidiaryCommonShares	357000
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	9511000
CY2022Q2	atai	Foreign Currency Translation Adjustment Net Of Tax ForeignCurrencyTranslationAdjustmentNetOfTax	-8452000
CY2022Q2	us-gaap	Net Income Loss Including Portion Attributable To Nonredeemable Noncontrolling Interest NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest	-37509000
CY2022Q2	atai	Stockholder Equity Including Portion Attributable To Noncontrolling Interest StockholderEquityIncludingPortionAttributableToNoncontrollingInterest	320122000
CY2020Q4	atai	Stockholder Equity Including Portion Attributable To Noncontrolling Interest StockholderEquityIncludingPortionAttributableToNoncontrollingInterest	95368000
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	4900000
CY2021Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	23510000
CY2021Q1	us-gaap	Noncontrolling Interest Increase From Subsidiary Equity Issuance NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance	885000
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	212000
CY2021Q1	atai	Foreign Currency Translation Adjustment Net Of Tax ForeignCurrencyTranslationAdjustmentNetOfTax	-4026000
CY2021Q1	us-gaap	Net Income Loss Including Portion Attributable To Nonredeemable Noncontrolling Interest NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest	4044000
CY2021Q1	atai	Stockholder Equity Including Portion Attributable To Noncontrolling Interest StockholderEquityIncludingPortionAttributableToNoncontrollingInterest	119993000
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	4900000
CY2021Q2	atai	Settlement Of Issuance Of Common Shares Value SettlementOfIssuanceOfCommonSharesValue	140868000
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	9000000.0
CY2021Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	231581000
CY2021Q2	us-gaap	Noncontrolling Interest Increase From Subsidiary Equity Issuance NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance	3649000
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	37512000
CY2021Q2	atai	Foreign Currency Translation Adjustment Net Of Tax ForeignCurrencyTranslationAdjustmentNetOfTax	2110000
CY2021Q2	us-gaap	Net Income Loss Including Portion Attributable To Nonredeemable Noncontrolling Interest NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest	-50818000
CY2021Q2	atai	Stockholder Equity Including Portion Attributable To Noncontrolling Interest StockholderEquityIncludingPortionAttributableToNoncontrollingInterest	484895000
	us-gaap	Profit Loss ProfitLoss	-75067000
	us-gaap	Profit Loss ProfitLoss	-49329000
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	79000
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	25000
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	0
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	191000
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-95000
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	660000
	us-gaap	Increase Decrease In Debt Securities Trading IncreaseDecreaseInDebtSecuritiesTrading	-1324000
	us-gaap	Increase Decrease In Debt Securities Trading IncreaseDecreaseInDebtSecuritiesTrading	0
	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	-0
	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	-41000
	atai	Change In Fair Value Of Warrant Liabilities ChangeInFairValueOfWarrantLiabilities	53000
	atai	Change In Fair Value Of Warrant Liabilities ChangeInFairValueOfWarrantLiabilities	-40000
	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	0
CY2021Q4	atai	Stockholder Equity Including Portion Attributable To Noncontrolling Interest StockholderEquityIncludingPortionAttributableToNoncontrollingInterest	385959000
CY2022Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	132000
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	10208000
CY2022Q1	atai	Foreign Currency Translation Adjustment Net Of Tax ForeignCurrencyTranslationAdjustmentNetOfTax	-4384000
CY2022Q1	us-gaap	Net Income Loss Including Portion Attributable To Nonredeemable Noncontrolling Interest NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest	-37558000
CY2022Q1	atai	Stockholder Equity Including Portion Attributable To Noncontrolling Interest StockholderEquityIncludingPortionAttributableToNoncontrollingInterest	354357000
CY2022Q2	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	1140000
CY2022Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	118000
CY2022Q2	atai	Issuance Of Subsidiary Preferred Shares IssuanceOfSubsidiaryPreferredShares	600000
CY2022Q2	atai	Issuance Of Subsidiary Common Shares IssuanceOfSubsidiaryCommonShares	357000
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	9511000
CY2022Q2	atai	Foreign Currency Translation Adjustment Net Of Tax ForeignCurrencyTranslationAdjustmentNetOfTax	-8452000
CY2022Q2	us-gaap	Net Income Loss Including Portion Attributable To Nonredeemable Noncontrolling Interest NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest	-37509000
CY2022Q2	atai	Stockholder Equity Including Portion Attributable To Noncontrolling Interest StockholderEquityIncludingPortionAttributableToNoncontrollingInterest	320122000
CY2020Q4	atai	Stockholder Equity Including Portion Attributable To Noncontrolling Interest StockholderEquityIncludingPortionAttributableToNoncontrollingInterest	95368000
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	4900000
CY2021Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	23510000
CY2021Q1	us-gaap	Noncontrolling Interest Increase From Subsidiary Equity Issuance NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance	885000
CY2021Q1	us-gaap	Net Income Loss Including Portion Attributable To Nonredeemable Noncontrolling Interest NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest	4044000
CY2021Q1	atai	Stockholder Equity Including Portion Attributable To Noncontrolling Interest StockholderEquityIncludingPortionAttributableToNoncontrollingInterest	119993000
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	4900000
CY2021Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	231581000
CY2021Q2	us-gaap	Noncontrolling Interest Increase From Subsidiary Equity Issuance NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance	3649000
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	37512000
CY2021Q2	atai	Foreign Currency Translation Adjustment Net Of Tax ForeignCurrencyTranslationAdjustmentNetOfTax	2110000
CY2021Q2	us-gaap	Net Income Loss Including Portion Attributable To Nonredeemable Noncontrolling Interest NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest	-50818000
CY2021Q2	atai	Stockholder Equity Including Portion Attributable To Noncontrolling Interest StockholderEquityIncludingPortionAttributableToNoncontrollingInterest	484895000
	us-gaap	Profit Loss ProfitLoss	-75067000
	us-gaap	Profit Loss ProfitLoss	-49329000
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	79000
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	25000
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	0
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	660000
	us-gaap	Increase Decrease In Debt Securities Trading IncreaseDecreaseInDebtSecuritiesTrading	-1324000
	us-gaap	Increase Decrease In Debt Securities Trading IncreaseDecreaseInDebtSecuritiesTrading	0
	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	-0
	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	-41000
	atai	Change In Fair Value Of Warrant Liabilities ChangeInFairValueOfWarrantLiabilities	53000
	atai	Change In Fair Value Of Warrant Liabilities ChangeInFairValueOfWarrantLiabilities	-40000
	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	0
	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	-5460000
	us-gaap	Equity Method Investment Realized Gain Loss On Disposal EquityMethodInvestmentRealizedGainLossOnDisposal	0
	us-gaap	Equity Method Investment Realized Gain Loss On Disposal EquityMethodInvestmentRealizedGainLossOnDisposal	16923000
	atai	Loss On Conversion Of Convertible Notes LossOnConversionOfConvertibleNotes	0
	atai	Loss On Conversion Of Convertible Notes LossOnConversionOfConvertibleNotes	513000
	us-gaap	Variable Interest Entity Initial Consolidation Gain Or Loss VariableInterestEntityInitialConsolidationGainOrLoss	0
	us-gaap	Variable Interest Entity Initial Consolidation Gain Or Loss VariableInterestEntityInitialConsolidationGainOrLoss	3543000
	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	-5460000
	us-gaap	Equity Method Investment Realized Gain Loss On Disposal EquityMethodInvestmentRealizedGainLossOnDisposal	0
	us-gaap	Equity Method Investment Realized Gain Loss On Disposal EquityMethodInvestmentRealizedGainLossOnDisposal	16923000
	atai	Loss On Conversion Of Convertible Notes LossOnConversionOfConvertibleNotes	0
	atai	Loss On Conversion Of Convertible Notes LossOnConversionOfConvertibleNotes	513000
	us-gaap	Variable Interest Entity Initial Consolidation Gain Or Loss VariableInterestEntityInitialConsolidationGainOrLoss	0
	us-gaap	Variable Interest Entity Initial Consolidation Gain Or Loss VariableInterestEntityInitialConsolidationGainOrLoss	3543000
	atai	Income Losses From Equity Method Investments IncomeLossesFromEquityMethodInvestments	12242000
	atai	Income Losses From Equity Method Investments IncomeLossesFromEquityMethodInvestments	4641000
	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	357000
	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	8934000
	us-gaap	Share Based Compensation ShareBasedCompensation	19720000
	us-gaap	Share Based Compensation ShareBasedCompensation	37724000
	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	4966000
	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	0
	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	-134000
	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	41000
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-939000
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1674000
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-2591000
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2380000
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	2328000
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-3846000
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	0
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	120000
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-45917000
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-14627000
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	172000
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	298000
	us-gaap	Payments To Develop Software PaymentsToDevelopSoftware	100000
	us-gaap	Payments To Develop Software PaymentsToDevelopSoftware	155000
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	229678000
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	0
	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	0
	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	47000
	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	0
	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	5359000
	us-gaap	Payments To Acquire Other Investments PaymentsToAcquireOtherInvestments	0
	us-gaap	Payments To Acquire Other Investments PaymentsToAcquireOtherInvestments	23445000
	us-gaap	Payments To Fund Longterm Loans To Related Parties PaymentsToFundLongtermLoansToRelatedParties	3000000
	us-gaap	Payments To Fund Longterm Loans To Related Parties PaymentsToFundLongtermLoansToRelatedParties	2624000
	us-gaap	Payments To Acquire Other Productive Assets PaymentsToAcquireOtherProductiveAssets	0
	us-gaap	Payments To Acquire Other Productive Assets PaymentsToAcquireOtherProductiveAssets	195000
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-232950000
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-32029000
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	409884000
	us-gaap	Payments For Repurchase Of Initial Public Offering PaymentsForRepurchaseOfInitialPublicOffering	0
	us-gaap	Payments For Repurchase Of Initial Public Offering PaymentsForRepurchaseOfInitialPublicOffering	10161000
	atai	Income Losses From Equity Method Investments IncomeLossesFromEquityMethodInvestments	12242000
	atai	Income Losses From Equity Method Investments IncomeLossesFromEquityMethodInvestments	4641000
	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	357000
	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	8934000
	us-gaap	Share Based Compensation ShareBasedCompensation	19720000
	us-gaap	Share Based Compensation ShareBasedCompensation	37724000
	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	4966000
	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	0
	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	-134000
	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	41000
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1674000
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-2591000
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2380000
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	2328000
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-3846000
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	0
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	120000
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-45917000
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-14627000
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	172000
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	298000
	us-gaap	Payments To Develop Software PaymentsToDevelopSoftware	100000
	us-gaap	Payments To Develop Software PaymentsToDevelopSoftware	155000
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	229678000
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	0
	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	0
	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	47000
	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	0
	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	5359000
	us-gaap	Payments To Acquire Other Investments PaymentsToAcquireOtherInvestments	0
	us-gaap	Payments To Acquire Other Investments PaymentsToAcquireOtherInvestments	23445000
	us-gaap	Payments To Fund Longterm Loans To Related Parties PaymentsToFundLongtermLoansToRelatedParties	3000000
	us-gaap	Payments To Fund Longterm Loans To Related Parties PaymentsToFundLongtermLoansToRelatedParties	2624000
	us-gaap	Payments To Acquire Other Productive Assets PaymentsToAcquireOtherProductiveAssets	0
	us-gaap	Payments To Acquire Other Productive Assets PaymentsToAcquireOtherProductiveAssets	195000
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-232950000
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-32029000
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	409884000
	us-gaap	Payments For Repurchase Of Initial Public Offering PaymentsForRepurchaseOfInitialPublicOffering	0
	us-gaap	Payments For Repurchase Of Initial Public Offering PaymentsForRepurchaseOfInitialPublicOffering	10161000
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	0
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	534000
	atai	Proceeds From Sale Of Investment ProceedsFromSaleOfInvestment	0
	atai	Proceeds From Sale Of Investment ProceedsFromSaleOfInvestment	2417000
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	249000
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0
	us-gaap	Proceeds From Issuance Of Trust Preferred Securities ProceedsFromIssuanceOfTrustPreferredSecurities	600000
	us-gaap	Proceeds From Issuance Of Trust Preferred Securities ProceedsFromIssuanceOfTrustPreferredSecurities	0
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	0
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	534000
	atai	Proceeds From Sale Of Investment ProceedsFromSaleOfInvestment	0
	atai	Proceeds From Sale Of Investment ProceedsFromSaleOfInvestment	2417000
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	249000
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0
	us-gaap	Proceeds From Issuance Of Trust Preferred Securities ProceedsFromIssuanceOfTrustPreferredSecurities	600000
	us-gaap	Proceeds From Issuance Of Trust Preferred Securities ProceedsFromIssuanceOfTrustPreferredSecurities	0
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	1077000
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0
	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	0
	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	1588000
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1926000
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	404262000
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-1193000
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-1230000
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-278134000
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	356376000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	362266000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	97246000
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	84132000
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	453622000
	atai	Right Of Use Asset Obtained In Exchange For Operating Lease Liabilities RightOfUseAssetObtainedInExchangeForOperatingLeaseLiabilities	487000
	atai	Right Of Use Asset Obtained In Exchange For Operating Lease Liabilities RightOfUseAssetObtainedInExchangeForOperatingLeaseLiabilities	0
	atai	Issuance Of Subsidiary Shares In Connection With A Stock Purchase Agreement IssuanceOfSubsidiarySharesInConnectionWithAStockPurchaseAgreement	357000
	atai	Issuance Of Subsidiary Shares In Connection With A Stock Purchase Agreement IssuanceOfSubsidiarySharesInConnectionWithAStockPurchaseAgreement	0
	atai	Common Stock Issuance Costs In Accounts Payable CommonStockIssuanceCostsInAccountsPayable	0
	atai	Common Stock Issuance Costs In Accounts Payable CommonStockIssuanceCostsInAccountsPayable	230000
	atai	Common Stock Issuance Costs In Accrued Liabilities CommonStockIssuanceCostsInAccruedLiabilities	0
	atai	Common Stock Issuance Costs In Accrued Liabilities CommonStockIssuanceCostsInAccruedLiabilities	1958000
	atai	Fair Value Of Non Controlling Interests Issued In Connection With Consolidation Of Variable Interest Entity FairValueOfNonControllingInterestsIssuedInConnectionWithConsolidationOfVariableInterestEntity	0
	atai	Fair Value Of Non Controlling Interests Issued In Connection With Consolidation Of Variable Interest Entity FairValueOfNonControllingInterestsIssuedInConnectionWithConsolidationOfVariableInterestEntity	392000
	atai	Fair Value Of Redeemable Non Controlling Interests Issued In Connection With Consolidation Of Variable Interest Entity FairValueOfRedeemableNonControllingInterestsIssuedInConnectionWithConsolidationOfVariableInterestEntity	0
	atai	Fair Value Of Redeemable Non Controlling Interests Issued In Connection With Consolidation Of Variable Interest Entity FairValueOfRedeemableNonControllingInterestsIssuedInConnectionWithConsolidationOfVariableInterestEntity	2555000
	us-gaap	Fair Value Of Assets Acquired FairValueOfAssetsAcquired	0
	us-gaap	Fair Value Of Assets Acquired FairValueOfAssetsAcquired	885000
	atai	Issuance Of Derivative Instrument Related To Convertible Promissory Notes IssuanceOfDerivativeInstrumentRelatedToConvertiblePromissoryNotes	0
	atai	Issuance Of Derivative Instrument Related To Convertible Promissory Notes IssuanceOfDerivativeInstrumentRelatedToConvertiblePromissoryNotes	646000
	atai	Issuance Of Subsidiary Shares In Connection With The Conversion Of Convertible Notes IssuanceOfSubsidiarySharesInConnectionWithTheConversionOfConvertibleNotes	0
	atai	Issuance Of Subsidiary Shares In Connection With The Conversion Of Convertible Notes IssuanceOfSubsidiarySharesInConnectionWithTheConversionOfConvertibleNotes	3257000
	us-gaap	Nature Of Operations NatureOfOperations	<p id="footnotes" style="text-indent:0.0%;font-size:10.0pt;margin-top:4.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">1. Or</span><span id="notes"/><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">ganization and Description of Business</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.35pt;line-height:5.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">ATAI Life Sciences N.V. (“atai”) is the parent company of ATAI Life Sciences AG and, along with its subsidiaries, is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. atai was founded in 2018 as a response to the significant unmet need and lack of innovation in the mental health treatment landscape. atai is dedicated to acquiring, incubating and efficiently developing innovative therapeutics to treat depression, anxiety, addiction, and other mental health disorders.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.75pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Since inception, atai has either created wholly owned subsidiaries or has made investments in certain controlled entities, including variable interest entities (“VIEs”) for which atai is the primary beneficiary under the VIE model (collectively, the “Company”). atai is headquartered in Berlin, Germany.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The Company has determined that it has one operating and reporting segment.</span></p><p style="margin-left:4.133%;text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Corporate Reorganization and Initial Public Offering</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.4pt;line-height:5.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">atai was incorporated pursuant to the laws of the Netherlands as a Dutch private company with limited liability on September 10, 2020 for the purposes of becoming a holding company for ATAI Life Sciences AG and consummating the corporate reorganization described below. atai did not conduct any operations prior to the corporate reorganization other than activities incidental to its formation. ATAI Life Sciences AG was formed as a separate company on February 7, 2018.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.85pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">In contemplation of the consummation of atai’s initial public offering (“IPO”) of common shares, atai undertook a corporate reorganization (the “Corporate Reorganization”). The Corporate Reorganization consisted of several steps as described below:</span></p><div style="margin-left:5.065%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:5.065%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:5.335229367461947%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Exchange of ATAI Life Sciences AG Securities for ATAI Life Sciences B.V. Common Shares and Share Split</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">: In April 2021, the existing shareholders of ATAI Life Sciences AG each became a party to a separate notarial deed of issue under Dutch law and (i) subscribed for new common shares in ATAI Life Sciences B.V. and (ii) transferred their respective shares in ATAI Life Sciences AG, on a </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">1 to 10 basis</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> (the “Exchange Ratio”), to ATAI Life Sciences B.V. as a contribution in kind on the common shares in ATAI Life Sciences B.V. As a result of the issuance of common shares in ATAI Life Sciences B.V. to the shareholders of ATAI Life Sciences AG and the contribution and transfer of their respective shares in ATAI Life Sciences AG to ATAI Life Sciences B.V., ATAI Life Sciences AG became a wholly owned subsidiary of ATAI Life Sciences B.V. No shareholder rights or preferences changed as a result of the share for share exchange. In connection with such exchange, the common share in ATAI Life Sciences B.V. held by Apeiron was cancelled. On June 7, 2021, shares of ATAI Life Sciences B.V. were split applying a ratio of </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">1.6 to one</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">, and the nominal value of the shares was reduced to €</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">0.10</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">, pursuant to a shareholders’ resolution and amendment to the articles of association.</span></div></div><div style="margin-left:5.065%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:5.065%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:5.335229367461947%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Conversion of ATAI Life Sciences B.V. into ATAI Life Sciences N.V</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">.: Immediately preceding the Company’s IPO, the legal form of ATAI Life Sciences B.V. was converted from a Dutch private company with limited liability to a Dutch public company, and the articles of association of ATAI Life Sciences N.V., became effective. Following the Corporate Reorganization, ATAI Life Sciences N.V. became the holding company of ATAI Life Sciences AG.</span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.85pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1452083333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The Corporate Reorganization, as described above, is considered a continuation of ATAI Life Sciences AG resulting in no change in the carrying values of assets or liabilities. As a result, the financial statements for periods prior to the Corporate Reorganization are the financial statements of ATAI Life Sciences AG as the predecessor to atai for accounting and reporting purposes. All share, per-share and related information presented in these condensed consolidated financial statements and corresponding disclosure notes have been retrospectively adjusted, where applicable, to reflect the impact of the share exchange and share split resulting from the Corporate Reorganization. In connection with the Corporate Reorganization, outstanding share awards and option grants of ATAI Life Sciences AG were exchanged for share awards and option grants of ATAI Life Sciences B.V. with identical restrictions.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:1.0pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1452083333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">On June 22, 2021, atai closed the IPO of its common shares on the Nasdaq Stock Market ("Nasdaq"). As part of the IPO, the Company issued and sold </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">17,250,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> shares of its common shares, which included </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">2,250,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> shares sold pursuant to the exercise of the underwriters’ over-allotment option, at a public offering price of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">15.00</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> per share. The Company received net proceeds of approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">231.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> million from the IPO, after deducting underwriters’ discounts and commissions of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">18.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> million and offering costs of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">9.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> million.</span></p><p style="margin-left:4.133%;text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Impact of COVID-19 Pandemic</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.35pt;line-height:5.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1452083333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The COVID-19 pandemic has continued to present global public health and economic challenges during the six months ended June 30, 2022. Although some research and development timelines have been impacted by delays related to the COVID-19 pandemic, the Company has not experienced material financial impacts on its business and operations as a result. The Company continues to monitor the impact of the COVID-19 pandemic on its employees and business and has undertaken business continuity measures to mitigate potential disruption to its operations.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The future impact of COVID-19 on the Company’s business and operations, including its research and development programs and related clinical trials, will largely depend on future developments, which are highly uncertain, such as the duration of the pandemic, the spread of the disease and variants thereof, the availability and effectiveness of vaccines and related roll-out efforts, breakthrough infections among the vaccinated, vaccine hesitancy, the implementation of vaccine mandates, travel restrictions, social distancing and related government actions around the world, business closures or business disruptions and the ultimate impact of COVID-19 on financial markets and the global economy.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p><p style="margin-left:4.133%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Liquidity and Going Concern</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.35pt;line-height:5.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The Company has incurred significant losses and negative cash flows from operations since its inception. As of June 30, 2022, the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Company had cash and cash equivalents of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">84.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> million, short-term securities of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">228.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> million and its accumulated deficit was $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">431.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> million. The</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> Company has historically financed its operations through the sale of equity securities, sale of convertible notes and revenue generated from licensing and collaboration arrangements. The Company has not generated any revenues to date from the sale of its product candidates and does not anticipate generating any revenues from the sale of its product candidates unless and until it successfully completes development and obtains regulatory approval to market its product candidates.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.75pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The Company currently expects that its existing cash and cash equivalents and short-term securities as of June 30, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> will be sufficient to fund its operating expenses and capital expenditure requirements for at least the next 12 months from the date the condensed consolidated financial statements are issued.</span></p>
	us-gaap	Common Stock Conversion Basis CommonStockConversionBasis	1 to 10 basis
CY2021Q2	us-gaap	Common Stock Conversion Basis CommonStockConversionBasis	1.6 to one
CY2021Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.10
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	84100000
CY2022Q2	us-gaap	Short Term Borrowings ShortTermBorrowings	228400000
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-431300000
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	1077000
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0
	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	0
	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	1588000
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1926000
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	404262000
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-1193000
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-1230000
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-278134000
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	356376000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	362266000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	97246000
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	84132000
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	453622000
	atai	Right Of Use Asset Obtained In Exchange For Operating Lease Liabilities RightOfUseAssetObtainedInExchangeForOperatingLeaseLiabilities	487000
	atai	Right Of Use Asset Obtained In Exchange For Operating Lease Liabilities RightOfUseAssetObtainedInExchangeForOperatingLeaseLiabilities	0
	atai	Issuance Of Subsidiary Shares In Connection With A Stock Purchase Agreement IssuanceOfSubsidiarySharesInConnectionWithAStockPurchaseAgreement	357000
	atai	Issuance Of Subsidiary Shares In Connection With A Stock Purchase Agreement IssuanceOfSubsidiarySharesInConnectionWithAStockPurchaseAgreement	0
	atai	Common Stock Issuance Costs In Accounts Payable CommonStockIssuanceCostsInAccountsPayable	0
	atai	Common Stock Issuance Costs In Accounts Payable CommonStockIssuanceCostsInAccountsPayable	230000
	atai	Common Stock Issuance Costs In Accrued Liabilities CommonStockIssuanceCostsInAccruedLiabilities	0
	atai	Common Stock Issuance Costs In Accrued Liabilities CommonStockIssuanceCostsInAccruedLiabilities	1958000
	atai	Fair Value Of Non Controlling Interests Issued In Connection With Consolidation Of Variable Interest Entity FairValueOfNonControllingInterestsIssuedInConnectionWithConsolidationOfVariableInterestEntity	0
	atai	Fair Value Of Non Controlling Interests Issued In Connection With Consolidation Of Variable Interest Entity FairValueOfNonControllingInterestsIssuedInConnectionWithConsolidationOfVariableInterestEntity	392000
	atai	Fair Value Of Redeemable Non Controlling Interests Issued In Connection With Consolidation Of Variable Interest Entity FairValueOfRedeemableNonControllingInterestsIssuedInConnectionWithConsolidationOfVariableInterestEntity	0
	atai	Fair Value Of Redeemable Non Controlling Interests Issued In Connection With Consolidation Of Variable Interest Entity FairValueOfRedeemableNonControllingInterestsIssuedInConnectionWithConsolidationOfVariableInterestEntity	2555000
	us-gaap	Fair Value Of Assets Acquired FairValueOfAssetsAcquired	0
	us-gaap	Fair Value Of Assets Acquired FairValueOfAssetsAcquired	885000
	atai	Issuance Of Derivative Instrument Related To Convertible Promissory Notes IssuanceOfDerivativeInstrumentRelatedToConvertiblePromissoryNotes	0
	atai	Issuance Of Derivative Instrument Related To Convertible Promissory Notes IssuanceOfDerivativeInstrumentRelatedToConvertiblePromissoryNotes	646000
	atai	Issuance Of Subsidiary Shares In Connection With The Conversion Of Convertible Notes IssuanceOfSubsidiarySharesInConnectionWithTheConversionOfConvertibleNotes	0
	atai	Issuance Of Subsidiary Shares In Connection With The Conversion Of Convertible Notes IssuanceOfSubsidiarySharesInConnectionWithTheConversionOfConvertibleNotes	3257000
	us-gaap	Nature Of Operations NatureOfOperations	<p id="footnotes" style="text-indent:0.0%;font-size:10.0pt;margin-top:4.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">1. Or</span><span id="notes"/><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">ganization and Description of Business</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.35pt;line-height:5.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">ATAI Life Sciences N.V. (“atai”) is the parent company of ATAI Life Sciences AG and, along with its subsidiaries, is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. atai was founded in 2018 as a response to the significant unmet need and lack of innovation in the mental health treatment landscape. atai is dedicated to acquiring, incubating and efficiently developing innovative therapeutics to treat depression, anxiety, addiction, and other mental health disorders.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.75pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Since inception, atai has either created wholly owned subsidiaries or has made investments in certain controlled entities, including variable interest entities (“VIEs”) for which atai is the primary beneficiary under the VIE model (collectively, the “Company”). atai is headquartered in Berlin, Germany.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The Company has determined that it has one operating and reporting segment.</span></p><p style="margin-left:4.133%;text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Corporate Reorganization and Initial Public Offering</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.4pt;line-height:5.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">atai was incorporated pursuant to the laws of the Netherlands as a Dutch private company with limited liability on September 10, 2020 for the purposes of becoming a holding company for ATAI Life Sciences AG and consummating the corporate reorganization described below. atai did not conduct any operations prior to the corporate reorganization other than activities incidental to its formation. ATAI Life Sciences AG was formed as a separate company on February 7, 2018.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.85pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">In contemplation of the consummation of atai’s initial public offering (“IPO”) of common shares, atai undertook a corporate reorganization (the “Corporate Reorganization”). The Corporate Reorganization consisted of several steps as described below:</span></p><div style="margin-left:5.065%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:5.065%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:5.335229367461947%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Exchange of ATAI Life Sciences AG Securities for ATAI Life Sciences B.V. Common Shares and Share Split</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">: In April 2021, the existing shareholders of ATAI Life Sciences AG each became a party to a separate notarial deed of issue under Dutch law and (i) subscribed for new common shares in ATAI Life Sciences B.V. and (ii) transferred their respective shares in ATAI Life Sciences AG, on a </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">1 to 10 basis</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> (the “Exchange Ratio”), to ATAI Life Sciences B.V. as a contribution in kind on the common shares in ATAI Life Sciences B.V. As a result of the issuance of common shares in ATAI Life Sciences B.V. to the shareholders of ATAI Life Sciences AG and the contribution and transfer of their respective shares in ATAI Life Sciences AG to ATAI Life Sciences B.V., ATAI Life Sciences AG became a wholly owned subsidiary of ATAI Life Sciences B.V. No shareholder rights or preferences changed as a result of the share for share exchange. In connection with such exchange, the common share in ATAI Life Sciences B.V. held by Apeiron was cancelled. On June 7, 2021, shares of ATAI Life Sciences B.V. were split applying a ratio of </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">1.6 to one</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">, and the nominal value of the shares was reduced to €</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">0.10</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">, pursuant to a shareholders’ resolution and amendment to the articles of association.</span></div></div><div style="margin-left:5.065%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:5.065%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:5.335229367461947%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Conversion of ATAI Life Sciences B.V. into ATAI Life Sciences N.V</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">.: Immediately preceding the Company’s IPO, the legal form of ATAI Life Sciences B.V. was converted from a Dutch private company with limited liability to a Dutch public company, and the articles of association of ATAI Life Sciences N.V., became effective. Following the Corporate Reorganization, ATAI Life Sciences N.V. became the holding company of ATAI Life Sciences AG.</span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.85pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1452083333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The Corporate Reorganization, as described above, is considered a continuation of ATAI Life Sciences AG resulting in no change in the carrying values of assets or liabilities. As a result, the financial statements for periods prior to the Corporate Reorganization are the financial statements of ATAI Life Sciences AG as the predecessor to atai for accounting and reporting purposes. All share, per-share and related information presented in these condensed consolidated financial statements and corresponding disclosure notes have been retrospectively adjusted, where applicable, to reflect the impact of the share exchange and share split resulting from the Corporate Reorganization. In connection with the Corporate Reorganization, outstanding share awards and option grants of ATAI Life Sciences AG were exchanged for share awards and option grants of ATAI Life Sciences B.V. with identical restrictions.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:1.0pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1452083333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">On June 22, 2021, atai closed the IPO of its common shares on the Nasdaq Stock Market ("Nasdaq"). As part of the IPO, the Company issued and sold </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">17,250,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> shares of its common shares, which included </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">2,250,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> shares sold pursuant to the exercise of the underwriters’ over-allotment option, at a public offering price of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">15.00</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> per share. The Company received net proceeds of approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">231.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> million from the IPO, after deducting underwriters’ discounts and commissions of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">18.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> million and offering costs of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">9.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> million.</span></p><p style="margin-left:4.133%;text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Impact of COVID-19 Pandemic</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.35pt;line-height:5.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1452083333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The COVID-19 pandemic has continued to present global public health and economic challenges during the six months ended June 30, 2022. Although some research and development timelines have been impacted by delays related to the COVID-19 pandemic, the Company has not experienced material financial impacts on its business and operations as a result. The Company continues to monitor the impact of the COVID-19 pandemic on its employees and business and has undertaken business continuity measures to mitigate potential disruption to its operations.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The future impact of COVID-19 on the Company’s business and operations, including its research and development programs and related clinical trials, will largely depend on future developments, which are highly uncertain, such as the duration of the pandemic, the spread of the disease and variants thereof, the availability and effectiveness of vaccines and related roll-out efforts, breakthrough infections among the vaccinated, vaccine hesitancy, the implementation of vaccine mandates, travel restrictions, social distancing and related government actions around the world, business closures or business disruptions and the ultimate impact of COVID-19 on financial markets and the global economy.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p><p style="margin-left:4.133%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Liquidity and Going Concern</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.35pt;line-height:5.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The Company has incurred significant losses and negative cash flows from operations since its inception. As of June 30, 2022, the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Company had cash and cash equivalents of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">84.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> million, short-term securities of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">228.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> million and its accumulated deficit was $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">431.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> million. The</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> Company has historically financed its operations through the sale of equity securities, sale of convertible notes and revenue generated from licensing and collaboration arrangements. The Company has not generated any revenues to date from the sale of its product candidates and does not anticipate generating any revenues from the sale of its product candidates unless and until it successfully completes development and obtains regulatory approval to market its product candidates.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.75pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The Company currently expects that its existing cash and cash equivalents and short-term securities as of June 30, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> will be sufficient to fund its operating expenses and capital expenditure requirements for at least the next 12 months from the date the condensed consolidated financial statements are issued.</span></p>
	us-gaap	Common Stock Conversion Basis CommonStockConversionBasis	1 to 10 basis
CY2021Q2	us-gaap	Common Stock Conversion Basis CommonStockConversionBasis	1.6 to one
CY2021Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.10
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	84100000
CY2022Q2	us-gaap	Short Term Borrowings ShortTermBorrowings	228400000
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-431300000
CY2022Q2	us-gaap	Notes Payable Fair Value Disclosure NotesPayableFairValueDisclosure	28800000
CY2022Q2	us-gaap	Notes Payable Fair Value Disclosure NotesPayableFairValueDisclosure	28800000
CY2021Q1	us-gaap	Minority Interest MinorityInterest	8603000
CY2021Q1	us-gaap	Minority Interest MinorityInterest	8603000
CY2021Q2	us-gaap	Noncontrolling Interest Increase From Subsidiary Equity Issuance NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance	3649000
	us-gaap	Use Of Estimates UseOfEstimates	<p style="margin-left:4.133%;text-indent:0.0%;font-size:10.0pt;margin-top:11.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.35pt;line-height:5.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Significant estimates and assumptions made in the accompanying condensed consolidated financial statements include, but are not limited to the fair value of the Company’s investment in Intelgenx Technologies Corp. (“IntelGenx”), securities carried at fair value, contingent consideration liability—related parties, in-process research and development assets (“IPRD”), redeemable noncontrolling interests and noncontrolling interests</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">recognized in acquisitions, the valuations of common shares prior to IPO and share-based awards, and accruals for research and development costs.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable. Actual results may differ from those estimates or assumptions.</span></p>
CY2022Q2	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	267232000
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	0
	us-gaap	Use Of Estimates UseOfEstimates	<p style="margin-left:4.133%;text-indent:0.0%;font-size:10.0pt;margin-top:11.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.35pt;line-height:5.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Significant estimates and assumptions made in the accompanying condensed consolidated financial statements include, but are not limited to the fair value of the Company’s investment in Intelgenx Technologies Corp. (“IntelGenx”), securities carried at fair value, contingent consideration liability—related parties, in-process research and development assets (“IPRD”), redeemable noncontrolling interests and noncontrolling interests</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">recognized in acquisitions, the valuations of common shares prior to IPO and share-based awards, and accruals for research and development costs.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable. Actual results may differ from those estimates or assumptions.</span></p>
CY2022Q2	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	267232000
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	0
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	200000
CY2022Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	100000
CY2022Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	100000
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	1000000.0
CY2022Q2	us-gaap	Equity Method Investment Ownership Percentage EquityMethodInvestmentOwnershipPercentage	0.80
CY2021Q4	us-gaap	Equity Method Investment Ownership Percentage EquityMethodInvestmentOwnershipPercentage	0.80
CY2021Q4	us-gaap	Minority Interest MinorityInterest	9051000
CY2022Q1	atai	Net Income Loss Attributable To Noncontrolling Interest Preferred NetIncomeLossAttributableToNoncontrollingInterestPreferred	-689000
CY2022Q1	us-gaap	Other Comprehensive Income Loss Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest	-11000
CY2022Q1	us-gaap	Minority Interest MinorityInterest	8351000
CY2022Q2	us-gaap	Noncontrolling Interest Increase From Subsidiary Equity Issuance NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance	957000
CY2022Q2	atai	Net Income Loss Attributable To Noncontrolling Interest Preferred NetIncomeLossAttributableToNoncontrollingInterestPreferred	-891000
CY2022Q2	us-gaap	Other Comprehensive Income Loss Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest	30000
CY2022Q2	us-gaap	Minority Interest MinorityInterest	8447000
CY2020Q4	us-gaap	Minority Interest MinorityInterest	4546000
CY2021Q1	us-gaap	Noncontrolling Interest Increase From Subsidiary Equity Issuance NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance	885000
CY2021Q1	atai	Net Income Loss Attributable To Noncontrolling Interest Common NetIncomeLossAttributableToNoncontrollingInterestCommon	870000
CY2021Q1	atai	Net Income Loss Attributable To Noncontrolling Interest Preferred NetIncomeLossAttributableToNoncontrollingInterestPreferred	2486000
CY2021Q1	us-gaap	Other Comprehensive Income Loss Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest	-184000
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	200000
CY2022Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	100000
CY2022Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	100000
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	1000000.0
CY2022Q2	us-gaap	Equity Method Investment Ownership Percentage EquityMethodInvestmentOwnershipPercentage	0.80
CY2021Q4	us-gaap	Equity Method Investment Ownership Percentage EquityMethodInvestmentOwnershipPercentage	0.80
CY2021Q4	us-gaap	Minority Interest MinorityInterest	9051000
CY2022Q1	atai	Net Income Loss Attributable To Noncontrolling Interest Preferred NetIncomeLossAttributableToNoncontrollingInterestPreferred	-689000
CY2022Q1	us-gaap	Other Comprehensive Income Loss Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest	-11000
CY2022Q1	us-gaap	Minority Interest MinorityInterest	8351000
CY2022Q2	us-gaap	Noncontrolling Interest Increase From Subsidiary Equity Issuance NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance	957000
CY2022Q2	atai	Net Income Loss Attributable To Noncontrolling Interest Preferred NetIncomeLossAttributableToNoncontrollingInterestPreferred	-891000
CY2022Q2	us-gaap	Other Comprehensive Income Loss Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest	30000
CY2022Q2	us-gaap	Minority Interest MinorityInterest	8447000
CY2020Q4	us-gaap	Minority Interest MinorityInterest	4546000
CY2021Q1	us-gaap	Noncontrolling Interest Increase From Subsidiary Equity Issuance NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance	885000
CY2021Q1	atai	Net Income Loss Attributable To Noncontrolling Interest Common NetIncomeLossAttributableToNoncontrollingInterestCommon	870000
CY2021Q1	atai	Net Income Loss Attributable To Noncontrolling Interest Preferred NetIncomeLossAttributableToNoncontrollingInterestPreferred	2486000
CY2021Q1	us-gaap	Other Comprehensive Income Loss Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest	-184000
CY2021Q2	us-gaap	Noncontrolling Interest Increase From Subsidiary Equity Issuance NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance	3649000
CY2021Q2	atai	Net Income Loss Attributable To Noncontrolling Interest Common NetIncomeLossAttributableToNoncontrollingInterestCommon	-2364000
CY2021Q2	atai	Net Income Loss Attributable To Noncontrolling Interest Preferred NetIncomeLossAttributableToNoncontrollingInterestPreferred	7000
CY2021Q2	us-gaap	Other Comprehensive Income Loss Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest	150000
CY2021Q2	us-gaap	Minority Interest MinorityInterest	10045000
CY2022Q2	us-gaap	Redeemable Noncontrolling Interest Equity Carrying Amount RedeemableNoncontrollingInterestEquityCarryingAmount	0
CY2021Q4	us-gaap	Redeemable Noncontrolling Interest Equity Carrying Amount RedeemableNoncontrollingInterestEquityCarryingAmount	0
CY2022Q2	us-gaap	Net Income Loss Attributable To Redeemable Noncontrolling Interest NetIncomeLossAttributableToRedeemableNoncontrollingInterest	0
CY2021Q2	us-gaap	Net Income Loss Attributable To Redeemable Noncontrolling Interest NetIncomeLossAttributableToRedeemableNoncontrollingInterest	0
CY2020Q4	us-gaap	Redeemable Noncontrolling Interest Equity Redemption Value RedeemableNoncontrollingInterestEquityRedemptionValue	0
CY2021Q1	atai	Issuance Of Redeemable Noncontrolling Interests IssuanceOfRedeemableNoncontrollingInterests	0
CY2021Q1	atai	Net Loss Attributable To Redeemable Noncontrolling Interests Common NetLossAttributableToRedeemableNoncontrollingInterestsCommon	0
CY2021Q1	us-gaap	Redeemable Noncontrolling Interest Equity Redemption Value RedeemableNoncontrollingInterestEquityRedemptionValue	0
CY2021Q2	atai	Issuance Of Redeemable Noncontrolling Interests IssuanceOfRedeemableNoncontrollingInterests	2555000
CY2021Q2	atai	Net Loss Attributable To Redeemable Noncontrolling Interests Common NetLossAttributableToRedeemableNoncontrollingInterestsCommon	-2555000
CY2021Q2	us-gaap	Redeemable Noncontrolling Interest Equity Redemption Value RedeemableNoncontrollingInterestEquityRedemptionValue	0
CY2022Q2	us-gaap	Variable Interest Entity Entity Maximum Loss Exposure Amount VariableInterestEntityEntityMaximumLossExposureAmount	9200000
CY2022Q2	us-gaap	Variable Interest Difference Between Carrying Amount And Maximum Exposure VariableInterestDifferenceBetweenCarryingAmountAndMaximumExposure	7000000.0
CY2021Q4	us-gaap	Variable Interest Entity Entity Maximum Loss Exposure Amount VariableInterestEntityEntityMaximumLossExposureAmount	11600000
CY2021Q4	us-gaap	Variable Interest Difference Between Carrying Amount And Maximum Exposure VariableInterestDifferenceBetweenCarryingAmountAndMaximumExposure	3800000
CY2022Q2	us-gaap	Equity Method Investments EquityMethodInvestments	1162000
CY2021Q4	us-gaap	Equity Method Investments EquityMethodInvestments	16131000
CY2022Q2	us-gaap	Other Long Term Investments OtherLongTermInvestments	9233000
CY2021Q4	us-gaap	Other Long Term Investments OtherLongTermInvestments	11628000
	atai	Equity Method Investment Shares Transaction Date EquityMethodInvestmentSharesTransactionDate	2026-12-31
	us-gaap	Subsidiary Or Equity Method Investee Cumulative Proceeds Received On All Transactions SubsidiaryOrEquityMethodInvesteeCumulativeProceedsReceivedOnAllTransactions	9600000
	us-gaap	Proceeds From Issuance Of Secured Debt ProceedsFromIssuanceOfSecuredDebt	2200000
	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	0
CY2021Q2	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	3000000.0
CY2022Q2	atai	Term Loan Impairment Loss Recognized TermLoanImpairmentLossRecognized	0
CY2021Q2	atai	Net Income Loss Attributable To Noncontrolling Interest Common NetIncomeLossAttributableToNoncontrollingInterestCommon	-2364000
CY2021Q2	atai	Net Income Loss Attributable To Noncontrolling Interest Preferred NetIncomeLossAttributableToNoncontrollingInterestPreferred	7000
CY2021Q2	us-gaap	Other Comprehensive Income Loss Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest	150000
CY2021Q2	us-gaap	Minority Interest MinorityInterest	10045000
CY2022Q2	us-gaap	Redeemable Noncontrolling Interest Equity Carrying Amount RedeemableNoncontrollingInterestEquityCarryingAmount	0
CY2021Q4	us-gaap	Redeemable Noncontrolling Interest Equity Carrying Amount RedeemableNoncontrollingInterestEquityCarryingAmount	0
CY2022Q2	us-gaap	Net Income Loss Attributable To Redeemable Noncontrolling Interest NetIncomeLossAttributableToRedeemableNoncontrollingInterest	0
CY2021Q2	us-gaap	Net Income Loss Attributable To Redeemable Noncontrolling Interest NetIncomeLossAttributableToRedeemableNoncontrollingInterest	0
CY2020Q4	us-gaap	Redeemable Noncontrolling Interest Equity Redemption Value RedeemableNoncontrollingInterestEquityRedemptionValue	0
CY2021Q1	atai	Issuance Of Redeemable Noncontrolling Interests IssuanceOfRedeemableNoncontrollingInterests	0
CY2021Q1	atai	Net Loss Attributable To Redeemable Noncontrolling Interests Common NetLossAttributableToRedeemableNoncontrollingInterestsCommon	0
CY2021Q1	us-gaap	Redeemable Noncontrolling Interest Equity Redemption Value RedeemableNoncontrollingInterestEquityRedemptionValue	0
CY2021Q2	atai	Issuance Of Redeemable Noncontrolling Interests IssuanceOfRedeemableNoncontrollingInterests	2555000
CY2021Q2	atai	Net Loss Attributable To Redeemable Noncontrolling Interests Common NetLossAttributableToRedeemableNoncontrollingInterestsCommon	-2555000
CY2021Q2	us-gaap	Redeemable Noncontrolling Interest Equity Redemption Value RedeemableNoncontrollingInterestEquityRedemptionValue	0
CY2022Q2	us-gaap	Variable Interest Entity Entity Maximum Loss Exposure Amount VariableInterestEntityEntityMaximumLossExposureAmount	9200000
CY2022Q2	us-gaap	Variable Interest Difference Between Carrying Amount And Maximum Exposure VariableInterestDifferenceBetweenCarryingAmountAndMaximumExposure	7000000.0
CY2021Q4	us-gaap	Variable Interest Entity Entity Maximum Loss Exposure Amount VariableInterestEntityEntityMaximumLossExposureAmount	11600000
CY2021Q4	us-gaap	Variable Interest Difference Between Carrying Amount And Maximum Exposure VariableInterestDifferenceBetweenCarryingAmountAndMaximumExposure	3800000
CY2022Q2	us-gaap	Equity Method Investments EquityMethodInvestments	1162000
CY2021Q4	us-gaap	Equity Method Investments EquityMethodInvestments	16131000
CY2022Q2	us-gaap	Other Long Term Investments OtherLongTermInvestments	9233000
CY2021Q4	us-gaap	Other Long Term Investments OtherLongTermInvestments	11628000
	atai	Equity Method Investment Shares Transaction Date EquityMethodInvestmentSharesTransactionDate	2026-12-31
	us-gaap	Subsidiary Or Equity Method Investee Cumulative Proceeds Received On All Transactions SubsidiaryOrEquityMethodInvesteeCumulativeProceedsReceivedOnAllTransactions	9600000
	us-gaap	Proceeds From Issuance Of Secured Debt ProceedsFromIssuanceOfSecuredDebt	2200000
	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	0
CY2021Q2	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	3000000.0
CY2022Q2	atai	Term Loan Impairment Loss Recognized TermLoanImpairmentLossRecognized	0
CY2022Q2	us-gaap	Contingent Consideration Classified As Equity Fair Value Disclosure ContingentConsiderationClassifiedAsEquityFairValueDisclosure	100000
CY2021Q4	us-gaap	Contingent Consideration Classified As Equity Fair Value Disclosure ContingentConsiderationClassifiedAsEquityFairValueDisclosure	100000
CY2021Q4	atai	Fair Value Of Common Stock By Applying Discount For Lack Of Marketability FairValueOfCommonStockByApplyingDiscountForLackOfMarketability	0.050
CY2022Q2	atai	Fair Value Of Common Stock By Applying Discount For Lack Of Marketability FairValueOfCommonStockByApplyingDiscountForLackOfMarketability	0.050
CY2022Q2	atai	Prepaid Research And Development Related Expenses PrepaidResearchAndDevelopmentRelatedExpenses	3828000
CY2021Q4	atai	Prepaid Research And Development Related Expenses PrepaidResearchAndDevelopmentRelatedExpenses	2692000
CY2022Q2	atai	Research And Development Tax Credit Current ResearchAndDevelopmentTaxCreditCurrent	226000
CY2021Q4	atai	Research And Development Tax Credit Current ResearchAndDevelopmentTaxCreditCurrent	742000
CY2022Q2	us-gaap	Prepaid Taxes PrepaidTaxes	5674000
CY2021Q4	us-gaap	Prepaid Taxes PrepaidTaxes	4664000
CY2022Q2	us-gaap	Prepaid Insurance PrepaidInsurance	72000
CY2021Q4	us-gaap	Prepaid Insurance PrepaidInsurance	3049000
CY2022Q2	us-gaap	Other Assets Current OtherAssetsCurrent	1322000
CY2021Q4	us-gaap	Other Assets Current OtherAssetsCurrent	756000
CY2022Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	11122000
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	11903000
CY2021Q1	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	152200000
CY2021Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	4900000
	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	200000
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	21035201
CY2022Q2	us-gaap	Contingent Consideration Classified As Equity Fair Value Disclosure ContingentConsiderationClassifiedAsEquityFairValueDisclosure	100000
CY2021Q4	us-gaap	Contingent Consideration Classified As Equity Fair Value Disclosure ContingentConsiderationClassifiedAsEquityFairValueDisclosure	100000
CY2022Q2	atai	Fair Value Of Common Stock By Applying Discount For Lack Of Marketability FairValueOfCommonStockByApplyingDiscountForLackOfMarketability	0.050
CY2021Q4	atai	Prepaid Research And Development Related Expenses PrepaidResearchAndDevelopmentRelatedExpenses	2692000
CY2022Q2	atai	Research And Development Tax Credit Current ResearchAndDevelopmentTaxCreditCurrent	226000
CY2021Q4	atai	Research And Development Tax Credit Current ResearchAndDevelopmentTaxCreditCurrent	742000
CY2022Q2	us-gaap	Prepaid Taxes PrepaidTaxes	5674000
CY2021Q4	us-gaap	Prepaid Taxes PrepaidTaxes	4664000
CY2022Q2	us-gaap	Prepaid Insurance PrepaidInsurance	72000
CY2021Q4	us-gaap	Prepaid Insurance PrepaidInsurance	3049000
CY2022Q2	us-gaap	Other Assets Current OtherAssetsCurrent	1322000
CY2021Q4	us-gaap	Other Assets Current OtherAssetsCurrent	756000
CY2022Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	11122000
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	11903000
CY2022Q2	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	0
CY2021Q4	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	-5000
CY2022Q2	us-gaap	Convertible Debt ConvertibleDebt	619000
CY2021Q4	us-gaap	Convertible Debt ConvertibleDebt	743000
CY2021Q2	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	100000
CY2021Q2	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	93000
CY2022Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	3869000
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	2667000
CY2022Q2	us-gaap	Taxes Payable Current TaxesPayableCurrent	6880000
CY2021Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	8137000
CY2022Q2	atai	Accrued External Research And Development Expenses Current AccruedExternalResearchAndDevelopmentExpensesCurrent	4322000
CY2021Q4	atai	Accrued External Research And Development Expenses Current AccruedExternalResearchAndDevelopmentExpensesCurrent	861000
CY2022Q2	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	2614000
CY2021Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	2832000
CY2022Q2	atai	Accrued Advisory Fees Current AccruedAdvisoryFeesCurrent	115000
CY2021Q4	atai	Accrued Advisory Fees Current AccruedAdvisoryFeesCurrent	169000
CY2022Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1113000
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	163000
CY2022Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	18913000
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	14829000
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	200000
CY2022Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	3869000
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	2667000
CY2022Q2	us-gaap	Taxes Payable Current TaxesPayableCurrent	6880000
CY2021Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	8137000
CY2022Q2	atai	Accrued External Research And Development Expenses Current AccruedExternalResearchAndDevelopmentExpensesCurrent	4322000
CY2021Q4	atai	Accrued External Research And Development Expenses Current AccruedExternalResearchAndDevelopmentExpensesCurrent	861000
CY2022Q2	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	2614000
CY2021Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	2832000
CY2022Q2	atai	Accrued Advisory Fees Current AccruedAdvisoryFeesCurrent	115000
CY2021Q4	atai	Accrued Advisory Fees Current AccruedAdvisoryFeesCurrent	169000
CY2022Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1113000
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	163000
CY2022Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	18913000
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	14829000
CY2022Q2	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	0
CY2021Q4	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	-5000
CY2022Q2	us-gaap	Convertible Debt ConvertibleDebt	619000
CY2021Q4	us-gaap	Convertible Debt ConvertibleDebt	743000
CY2021Q2	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	100000
CY2021Q2	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	93000
	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	200000
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	200000
CY2021Q1	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	152200000
CY2021Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	4900000
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	21035201
CY2022Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	51000
CY2021Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	58000
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	92000
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	64000
CY2022Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	51000
CY2021Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	58000
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	92000
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	64000
CY2022Q2	us-gaap	Profit Loss ProfitLoss	-37509000
CY2021Q2	us-gaap	Profit Loss ProfitLoss	-53373000
	us-gaap	Profit Loss ProfitLoss	-75067000
	us-gaap	Profit Loss ProfitLoss	-49329000
CY2022Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-891000
CY2021Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-4912000
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-1580000
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-1556000
CY2022Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-36618000
CY2022Q2	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-36618000
CY2021Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-48461000
CY2021Q2	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-48461000
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-73487000
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-73487000
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-47773000
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-47773000
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	153971202
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	153971202
CY2021Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	132265075
CY2021Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	132265075
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	153751456
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	153751456
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	125797732
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	125797732
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.24
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.24
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.37
CY2021Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.37
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.48
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.48
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.38
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.38
CY2022Q2	us-gaap	Profit Loss ProfitLoss	-37509000
	us-gaap	Profit Loss ProfitLoss	-75067000
	us-gaap	Profit Loss ProfitLoss	-49329000
CY2022Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-891000
CY2021Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-4912000
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-1580000
CY2022Q2	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-36618000
CY2021Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-48461000
CY2021Q2	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-48461000
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-73487000
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-73487000
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-47773000
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	153971202
CY2021Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	132265075
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	153751456
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	125797732
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	125797732
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.24
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.24
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.37
CY2021Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.37
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.48
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.48
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.38
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.38
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	51019091
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	47079369
CY2021Q1	us-gaap	Accrued Payroll Taxes Current And Noncurrent AccruedPayrollTaxesCurrentAndNoncurrent	800000
CY2020Q3	atai	Related Party Reservation Rate Of Common Shares For Ipo RelatedPartyReservationRateOfCommonSharesForIpo	0.27
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	51019091
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	47079369
	us-gaap	Lease Cost LeaseCost	1800000
CY2021Q1	us-gaap	Accrued Payroll Taxes Current And Noncurrent AccruedPayrollTaxesCurrentAndNoncurrent	800000
CY2020Q3	atai	Related Party Reservation Rate Of Common Shares For Ipo RelatedPartyReservationRateOfCommonSharesForIpo	0.27

Files In Submission

Name	View Source	Status
0000950170-22-017253-index-headers.html	Edgar Link	pending
0000950170-22-017253-index.html	Edgar Link	pending
0000950170-22-017253.txt	Edgar Link	pending
0000950170-22-017253-xbrl.zip	Edgar Link	pending
atai-20220630.htm	Edgar Link	pending
atai-20220630.xsd	Edgar Link	pending
atai-ex31_1.htm	Edgar Link	pending
atai-ex31_2.htm	Edgar Link	pending
atai-ex32_1.htm	Edgar Link	pending
atai-ex32_2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
img105018067_0.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
atai-20220630_lab.xml	Edgar Link	unprocessable
atai-20220630_cal.xml	Edgar Link	unprocessable
atai-20220630_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
atai-20220630_htm.xml	Edgar Link	completed
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
atai-20220630_def.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ATAI
ATAI Life Sciences NV Stock $atai

2022 Q3 Form 10-Q Financial Statement

#000095017022017253 Filed on August 15, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ATAI ATAI Life Sciences NV Stock $atai

2022 Q3 Form 10-Q Financial Statement

#000095017022017253 Filed on August 15, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ATAI
ATAI Life Sciences NV Stock $atai